Physician profile
Amanda Williams
NPI 1629289657
$18,315.03
in general payments reported to CMS, 2019-2025
27 companies · $713 in 2025
The $713 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.33 · 2020: $274 · 2021: $320 · 2022: $222 · 2023: $11K · 2024: $5,785 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $11K · Travel and Lodging: $4,858 · Food and Beverage: $2,016 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $10,551.32 |
| Travel and Lodging | $4,858.01 |
| Food and Beverage | $2,016.35 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $16,059.47 | 2023-2024 | Davinci Xi, Da Vinci Surgical System |
| Abbvie INC. | $325.81 | 2020-2025 | Liletta, Orilissa, Lo Loestrin Fe |
| Evofem Biosciences, INC. | $322.34 | 2020-2025 | Phexxi, Solosec, Phexx |
| Astellas Pharma US INC | $198.76 | 2023-2025 | Veozah |
| Supernus Pharmaceuticals, INC. | $198.19 | 2023-2025 | Qelbree, Qelbree |
| Mayne Pharma Commercial LLC | $167.53 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $154.92 | 2025 | Myfembree, Gemtesa |
| Lupin INC. | $132.40 | 2019-2020 | |
| Hologic Sales and Service, LLC | $123.81 | 2025 | Novasure, Myosure Tissue Removal Device, Acessa Provu System |
| Ironshore Pharmaceuticals INC. | $101.92 | 2019-2023 | Jornay Pm |
| Sage Therapeutics, LLC | $81.83 | 2021-2025 | Zurzuvae |
| Lilly USA, LLC | $72.21 | 2025 | Zepbound, Mounjaro |
| Pfizer INC. | $66.99 | 2022-2023 | |
| Axsome Therapeutics, INC. | $64.33 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $34.95 | 2019-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $22.87 | 2023 | Myrisk |
| Smith+Nephew, INC. | $22.58 | 2024 | Pico |
| Shield Therapeutics INC | $20.76 | 2025 | |
| Exeltis, USA INC. | $20.16 | 2024 | Slynd |
| Amag Pharmaceuticals, INC. | $19.17 | 2020 | |
| Novo Nordisk INC | $18.61 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $17.24 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.92 | 2025 | Trintellix |
| Merck Sharp & Dohme LLC | $14.70 | 2019 | |
| Millicent US INC | $13.99 | 2025 | Femlyv |
| Vertex Pharmaceuticals Incorporated | $13.77 | 2025 | |
| Organon LLC | $9.80 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.